U.S. health officials are supporting a more convenient approach to cervical cancer prevention, which is not widely available in Canada. The Health Resources and Services Administration has released new guidelines that will eventually make it easier for women and individuals assigned female at birth to access at-home self-testing kits for the human papillomavirus (HPV), a sexually transmitted infection that can lead to cervical cancer. This shift is part of a move away from the traditional Pap test in favor of HPV tests, which can be conducted by either a healthcare provider or the individual.
Early detection of cervical cancer through regular screening can result in a 90 percent five-year survival rate. While many regions in Canada now recommend HPV screening instead of the Pap test for cervical cancer prevention, self-administered tests are not widely available outside of British Columbia. Here is a breakdown of HPV self-testing and its accessibility.
How do the at-home tests function?
The at-home HPV testing kits operate similarly to the rapid COVID-19 virus tests conducted at home. A swab is utilized to collect a sample from the vaginal area without the need for a speculum, unlike a Pap test or clinician-administered HPV test. The self-testing swab does not come into contact with the cervix, reducing the discomfort associated with a Pap test.
There is no instant result like with a COVID-19 test; the HPV screening sample must be sent to a lab for analysis. Self-collection not only allows for private testing at a convenient time but also encourages more individuals to undergo HPV screening, including those who have never been tested or do so infrequently, according to the Canadian Partnership Against Cancer.
How do the outcomes compare?
Pap smears detect abnormal or precancerous cervical cells with an accuracy of less than 60 percent, as per a 2022 study in the Canadian Medical Association Journal. Conversely, HPV testing examines the virus’s DNA rather than the patient’s cells and boasts an accuracy rate of over 90 percent in detecting the virus, as indicated by the same study.
Nearly all cervical cancer cases are caused by HPV, with certain strains responsible for over 70 percent of cases globally. A positive HPV test does not guarantee cancer development but may necessitate further evaluation, potentially including a Pap test. However, there are exceptional cases where HPV testing might not be helpful in detection.
Health Canada recommends Pap tests every three years and HPV screening every five years. British Columbia initiated a self-screening program for cervical cancer in January 2024. Prince Edward Island piloted self-testing in 2024 and plans to implement a phased clinical rollout after guideline review. Other provinces, such as Alberta, Manitoba, and Newfoundland and Labrador, have conducted self-screening pilot projects. Ontario offers HPV self-testing, though it is not covered by the provincial insurance program.
In the U.S., new recommendations allow women and individuals assigned female at birth aged 30 to 65, with average cervical cancer risk, to opt for self-testing. Starting January 1, 2027, most private insurance companies will be mandated to cover the test costs. Individuals can still choose clinician-performed HPV tests or Pap smears.
The American Cancer Society estimates around 13,000 new cervical cancer cases annually in the U.S., leading to approximately 4,300 deaths each year from the disease.
How prevalent are HPV and cervical cancer?
Health Canada reports that 75 percent of sexually active individuals will acquire at least one HPV infection in their lifetime, often without symptoms. Vaccination against carcinogenic and non-cancerous HPV strains has contributed to a reduction in cases, though recent data suggests a plateau. Cervical cancer rates declined steadily in Canada from 1984 to 2005 but have since leveled off. A report from the Canadian Cancer Statistics Advisory Committee underscores the preventability of the 430 anticipated cervical cancer deaths in 2025.
After years of decreasing cervical cancer rates, a recent Canadian Cancer Society report highlights a stall in progress toward eliminating the disease. Expanded access to HPV testing and vaccination is seen as a potential solution.
